{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(2)"],"submitter":["Ju H"],"pubmed_abstract":["<h4>Importance</h4>The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is still controversial.<h4>Objective</h4>To investigate the association of late onset MOGAD with moderate disability and relapse in Korean patients.<h4>Design, setting, and participants</h4>This nationwide, multicenter, retrospective cohort study included adult patients with a diagnosis of MOGAD according to the 2023 international diagnostic criteria between August 2018 and September 2024 across 28 hospitals in South Korea.<h4>Exposure</h4>Age at onset of MOGAD, categorized into adult-onset MOGAD (AO-MOGAD; 18-49 years) and late-onset MOGAD (LO-MOGAD; ≥50 years).<h4>Main outcomes and measures</h4>The primary outcomes were time to first relapse in patients with a disease du"],"journal":["JAMA network open"],"pagination":["e2559471"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905660"],"repository":["biostudies-literature"],"pubmed_title":["Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease."],"pmcid":["PMC12905660"],"pubmed_authors":["Kim SW","Shin HY","Ju W","Lee S","Kim H","Lee TK","Oh J","Nam TS","Sohn E","Ahn SW","Park MS","Lee HS","Park JW","Kim SH","Oh SI","Lee HL","Seok JM","Kim KH","Kang YR","Chung YH","Kim SM","Kwon S","Yang J","Oh SY","Kim HJ","Bae JS","Kim JK","Yoon BA","Woo SY","Kim BJ","Lim YM","Seok HY","Ju H","Kim S","Bong JB","Min JH","Lee EJ","Kim W","Joo IS","Kwon YN","Kim JE","Kim NH"],"additional_accession":[]},"is_claimable":false,"name":"Disability and Relapse Risk in Late-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.","description":"<h4>Importance</h4>The impact of late onset in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is still controversial.<h4>Objective</h4>To investigate the association of late onset MOGAD with moderate disability and relapse in Korean patients.<h4>Design, setting, and participants</h4>This nationwide, multicenter, retrospective cohort study included adult patients with a diagnosis of MOGAD according to the 2023 international diagnostic criteria between August 2018 and September 2024 across 28 hospitals in South Korea.<h4>Exposure</h4>Age at onset of MOGAD, categorized into adult-onset MOGAD (AO-MOGAD; 18-49 years) and late-onset MOGAD (LO-MOGAD; ≥50 years).<h4>Main outcomes and measures</h4>The primary outcomes were time to first relapse in patients with a disease du","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T15:44:39.248Z","creation":"2026-07-06T03:11:58.962Z"},"accession":"S-EPMC12905660","cross_references":{"pubmed":["41686435"],"doi":["10.1001/jamanetworkopen.2025.59471"]}}